A preliminary analysis of interleukin-1 ligands as potential predictive biomarkers of response to cetuximab

BACKGROUND: The epidermal growth factor receptor (EGFR) monoclonal IgG(1) antibody cetuximab is approved for first-line treatment of recurrent and metastatic (R/M) HNSCC as a part of the standard of care EXTREME regimen (platinum/5-fluorouracil/cetuximab). This regimen has relatively high response a...

Descripción completa

Detalles Bibliográficos
Autores principales: Espinosa-Cotton, Madelyn, Fertig, Elana J., Stabile, Laura P., Gaither-Davis, Autumn, Bauman, Julie E., Schmitz, Sandra, Gibson-Corley, Katherine N., Cheng, Yinwen, Jensen, Isaac J., Badovinac, Vladimir P., Laux, Douglas, Simons, Andrean L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6636109/
https://www.ncbi.nlm.nih.gov/pubmed/31346466
http://dx.doi.org/10.1186/s40364-019-0164-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6636109/
https://www.ncbi.nlm.nih.gov/pubmed/31346466
http://dx.doi.org/10.1186/s40364-019-0164-0

Ejemplares similares